ClinicaliQ Trial Snapshot
- Serological and PCR Testing for COVID-19 — Recruiting • Respiratory / COPD / Asthma • NCT04404062.
- What is being tested: The trial evaluates existing and newly developed COVID-19 PCR and antibody (serological) tests to establish methodologies that deliver rapid and accurate diagnostic results for SARS-CoV-2 infection.
- Patient eligibility overview: The study includes individuals with suspected or confirmed COVID-19 infection across various clinical presentations, enabling evaluation of test performance across different patient populations and disease stages.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. RRI are currently carrying out the following tests: A. Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens helps to assess whether an individual has…
Eligibility Snapshot
- : * Male or female aged 5 to 70 years. * An understanding, ability, and willingness to fully comply with the project procedures and restrictions.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.